Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of April 2026. The filing details a share repurchase executed on April 1, 2026, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing provides specific data regarding the share repurchase activity but does not contain revenue, profit, cash flow, margin, or debt figures.
- Shares Purchased (April 1, 2026): 345,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,086.00 GBp; highest price paid was 2,122.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,106.14 GBp.
- Cumulative Buyback (since Feb 17, 2026): 16,566,521 ordinary shares.
- Treasury Shares Held: 256,457,615 ordinary shares.
- Shares in Issue (excluding Treasury): 4,059,722,166 ordinary shares.
- Total Voting Rights: 4,059,722,166.
- Treasury Voting Rights Percentage: 6.32%.
Material Changes
There are no material changes to financial performance metrics reported in this filing. The primary change is the reduction in the number of shares in issue and the increase in treasury shares held by the Company following the April 1 repurchase. The filing confirms the Company's ongoing commitment to its capital return strategy via the buyback programme.
Guidance, Outlook, and Risks
The filing does not provide new financial guidance or management commentary on operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Investors are directed to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025 for a detailed description of these risks.
Important Facts for Investors to Verify
- Confirm the total remaining authorization under the buyback programme announced on February 17, 2026, to assess future capital return capacity.
- Verify the impact of the 6.32% treasury share holding on earnings per share (EPS) calculations and voting rights thresholds.
- Review the Annual Report on Form 20-F for 2025 to understand the specific risk factors referenced in the cautionary statement.
- Monitor subsequent filings to track the progress of the buyback programme against the cumulative total of 16.57 million shares purchased to date.